Sucampo Pharmaceuticals — Investor Presentation (September 2013)
27 slides from Sucampo Pharmaceuticals's investor presentation, Sep 25, 2013
Slide 1: Sucampo: The Science of Innovation
Silvia Taylor, SVP, IR, PR & Corporate Communications e 3 SUCAMPO The Science of Innovation
Slide 2: Agenda
Agenda 1. Introductions and Forward-Looking Statements 2. Company Introduction & Value Proposition 3. Commercial-Stage Company a) AMITIZA® Update b) RESCULA® Update . Prostone Platform Technology . Pipeline Update Financials Review . Upcoming Milestones & Recent Events eai/niolalr Conclusion ¢ 2 $ S
Slide 3: Forward-Looking Statements
Looking Statements This presentation contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materiall
Slide 4: Sucampo Value Proposition
Sucampo Value PropositionCommercial=Stage, Global Biopharmaceutical“Gompany « AMITIZA (lubiprostone) in gastroenterology Approved for chronic idiopathic constipation (CIC), iritable bowel syndrome Two FDA-Approved with constipation (IBS-C), and opioid-induced constipation (OIC) Drugs + RESCULA (unop
Slide 5: AMITIZA U.S.
AMITIZAU.S OIC IndicationApproved in April 2013 + $10M milestone payment received * Large market with 2.5-4.5M' potential patients * Takeda has added additional targets + AWIITIZA usage among pain specialists and anesthesiologists up 24%? Strong AMITIZA YOY Growth * Takeda reported net sales increas
Slide 6: AMITIZA US OIC Launch: Building on Strengths and Heritage
AMITIZAUS OIC Launch: Building on Strengths and Heritage ; 7M prescriptions over 7 years | | Pregnancy warning removed from label | AMITIZA MIMIC MEY Provides Sustained Relief Relieves Bloating/Discomfort R Build on Strength =, in Long-Term Safety | t Build on Strength Relieves Abdominal Pain 62.4 L
Slide 7: Global AMITIZA Approvals and Regulatory Filings
Global AMITIZA Approvals and Regulatory Filings AMITIZA has been used for >7 y with 7M prescriptions by patients suffering from CIC and IBS-C Switzerland CIC (2009) OIC (filed) cic (2012) Japan Olc (filed) CC (2012) us CIC (2006) IBS-C (2008) OIC Approved (April 2013) e 3 SUCAMPO The Science of Inno
Slide 8: AMITIZA Global Snapshot
AMITIZA Global Snapshot Japan Sucampo Japan sales up 49% to ~$3.3M Q2 vs. Q1° Over 70% of surveyed doctors will maintain or increase AMITIZA prescriptions® + Topreasons for uselof AMITIZA are unique MoA and efficacy 2 week limitation removal effective December Europe Commenced active marketing (CIC)
Slide 9: AMITIZA Intellectual Property
AMITIZA Intellectual Property AMITIZA has a robust patent estate + 13 patents + Latest patents expire in 2027 Paragraph IV certification notice letter to Sucampo received on January 2, 2013 regarding ANDA submitted to FDA by Anchen Pharmaceuticals + Notice letter alleges the 126 claims in AMITIZA’s
Slide 10: RESCULA Market Overview
RESCULA Market Overview Glaucoma is age-related; 24 leading cause of bilateral blindness WW + 2.2M people affected by Open Angle Glaucoma’ + Projected to grow to 3.4M by 2020 due to aging population” + Additional 3-6M patients with Ocular Hypertension® + Reduction in intra-ocular pressure (IOP) is c
Slide 11: RESCULA U.S.
RESCULA U.S. Favorable Feedback and Progress * Over 40,000 details to ophthalmologists and optometrists * Samples beginning to move through the system * 75% of RESCULA prescribers having a favorable experience’? * RESCULA'ssafety and tolerability profile key? Ongoing Efforts + Peer-to-peer programs
Slide 12: Sucampo's Proprietary Prostone Platform Technology
Sucampo's Proprietary Prostone Platform Technology Sucampo: Only company developing and commercializing prostone compounds globally Prostones: + Functional fatty acids naturally occuring in the human body + lon-channel activators + Physiological mediators of restoration of cellular homeostasis and t
Slide 13: Fluid Secretion
Fluid Secretion RESCULA % Smooth Muscle Relaxation Barrier Repair and Mucosal Protection Nerve Stabilization ¥ Anti-Inflammatory Activity See Reference 11 Prevents Neuronal Cell Death e 3 SUCAMPO The Science of Innovation
Slide 14: Clinical Focus and Stage of Clinical Development
CLINICAL FOCUS STAGE OF CLINICAL DEVELOPMENT LEAD COMPOUNDS DISCOVERY | PRECLINICAL PHASE 1 PHASE2 PHASE3 Unoprostone Isopropyl Retinitis Pigmentosa JapaniU.S." EEE EE | AMITIZA Pediatric Constipation FPFV2H13 = SS. EE EEE SPI-3608 PO Spinal Stenosis SPI-017 IV Spinal Stenosis Phase 1b Cobiprostone
Slide 15: AMITIZA Clinical Development & Life Cycle Management
AMITIZA Clinical Development & Life Cycle Management Pediatric Constipation + Very common GI complaint in children'? WW prevalence ~18% * Initiate P3 Pediatric Functional Constipation program 2H 2013 Potential to be 1% Rx constipation product for pediatric patients ‘Abdominal radiograph + Takeda: fu
Slide 16: Sucampo Prostone Pipeline Key Highlights (cont)
Sucampo Prostone Pipeline Key Highlights (cont) SPI-017 / SPI-3608 for Lumbar Spinal Stenosis LumbarSpinal Stenosis + Degenerative change in lumbar spine + Commonly observed in growing aged population + More than 400,000 Americans, most >60 years of age, may be suffering from symptoms caused by lumb
Slide 17: Key Facts
[ Key Facts | Trading Symbol SCMP (NASDAQ) Corporate Headquarters Bethesda, MD Stock Price (09-23-13), 52-Week Range $6.14, $10.48 to $4.41 Shares Outstanding (09-23-13) 42.5M (1 class of common stock) Daily Volume (90-day average) 447,287 Market Capitalization (09-23-13) $260.8M Enterprise Value (0
Slide 18: Q2 2013 Financial Highlights
Q2 2013 Financial Highlights Repurchased $2.3M of Sucampo shares since inception + Authorized amount: up to $5M * Offset any dilution resulting from the exercise of stock options in the fiscal year Financial Guidance + Approximately break-even in 2013 + Profitable in 2014 + In future will consider a
Slide 19: Milestones: Progress on 2013 Goals
Zz Obtain approval of OIC sNDA: Q2 2013 $10M milestone payment upon commercial launch of OIC Grow sales in Japan in 2013 Oo — v v QO) Pursue strategic alliances; new AMITIZA indications / territories v AMITIZA v¥ Submit for regulatory approval of OIC in Switzerland and UK by Q1 2013 =U Use MHRA appr
Slide 20: Upcoming Milestones
Start of phase ‘1b trial of cobiprostone for Oral Mucositis Top-line results of phase 2a trial of SPI-017 for Lumbar Spinal Stenosis 2H Start of phase 3 trial of AMITIZA for Pediatric Functional Constipation CEO Transition (EST) AMITIZA OIC indication potential approval in Switzerland / UK $ sucampo
Slide 21: Conclusion
Conclusion + AMITIZA® (lubiprostone) in gastroenterology Approved for chronic idiopathic constipation (CIC), irritable bowel syndrome Two FDA-Approved with constipation (IBS-C), and opioid-induced constipation (OIC) Drugs + RESCULA® (unoprostone isopropyl) in ophthalmics Approved for the lowering of
Slide 22: € SUCAMPO
€ 22 3 SUCAMPO The Science of Innovation
Slide 23: Key Facts and Financial Highlights
Trading Symbol SCMP (NASDAQ) : — i) | Corporate Headquarters Bethesda, MD Debt Stock Price (09-23-13), 52- | $6.14, $10.48to Cash& Equivalents $93.5M Week Range $4.41 Total OperatingExpense | $33.2M Shares Outstanding (09-23- | 42.5M (1 class of Total Revenue $43.9M 13) common stock) Net Income $3.0
Slide 24: Terms of Sucampo's AMITIZA Agreements
Terms of Sucampo’s AMITIZA Agreements Takeda Agreement + Takeda shall promote, market, and sell AMITIZA in US and Canada + Sucampo’s tiered royalty rate: 18%-26% of annual net sales + Sucampo earned $20M in upfront and $140M in development milestone payments as of 06/30/13 + Sucampo received $10M mi
Slide 25: Issued Lubiprostone US Patents
Issued Lubiprostone US Patents US Patent No. Expires Type of Patent 5,284,858 2014 ‘Compostion of matter (drug substance) 6,414,016 2020 Therapeuticuse (treating constipation) 6,583,174 2020 ‘Compostion of matter (drug product) 6,982,283 2022 Therapeuticuse (eating O10) 7,084,148 2022 Therapeutics (
Slide 26: Issued Patents
Issued Patents Lubiprostone Ex US 4332316 2023 ‘Composttion of matter (drug substance and drug product) 4,332,353 2022 Therapeuticuse (treating O10) 4,684,334 2023 Therapeuticuse (treating constipation) 4,783,794 2028 ‘Composttion of matter (drug product) 4,786,866 2023 ‘Therapeuticuse (treating con
Slide 27: References
References Clearview Analysis 2008 Internal Research IMS SmartView, NPA Report, client Factored Numbers, August 2012-August 2013 AMITIZA Physician ATU W114 2013 ImpactTrack survey 2013 Quigley ez al Br J Ophthaimot 2006 Mar;90(3):252-7 ‘American Academy of Ophthalmology Glaucoma Panel. Preferred Pra
Sucampo Pharmaceuticals — Investor Presentation (September 2013) on 6ix